hMN14 (labetuzumab)

DRUG4 trials

Sponsors

Gilead Sciences

Conditions

Breast CancerBreast NeoplasmsColon CancerColorectal CancerColorectal CarcinomaColorectal NeoplasmsColorectal TumorPancreatic Neoplasms

Phase 1

Safety Study of 90Y-hMN14 to Treat Colorectal Cancer

CompletedNCT00040599

Gilead SciencesColon Cancer, Colorectal Cancer, Colorectal Carcinoma +3

Start: 2000-01-31End: 2004-01-31Target: 72Updated: 2021-08-19

Safety Study of 90Y-hMN14 to Treat Colorectal Cancer Patients With Limited Residual Disease After Surgery

TerminatedNCT00041691

Gilead SciencesColorectal Neoplasms

Target: 30Updated: 2021-08-19

Safety Study of 90Y-hMN14 to Treat Pancreatic Cancer

CompletedNCT00041639

Gilead SciencesPancreatic Neoplasms

Start: 2000-01-31End: 2003-12-31Target: 75Updated: 2021-08-19

Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer

CompletedNCT00041652

Gilead SciencesBreast Cancer, Breast Neoplasms, Colon Cancer +4

Start: 2000-02-29End: 2003-06-30Target: 30Updated: 2021-08-19